- Home
- TRVI vs BBNX Comparison
TRVI vs BBNX Comparison
Compare TRVI & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- BBNX
- Stock Information
- Founded
- TRVI 2011
- BBNX 2015
- Country
- TRVI United States
- BBNX United States
- Employees
- TRVI N/A
- BBNX N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- TRVI Health Care
- BBNX Health Care
- Exchange
- TRVI Nasdaq
- BBNX Nasdaq
- Market Cap
- TRVI 725.7M
- BBNX 740.7M
- IPO Year
- TRVI 2019
- BBNX 2025
- Fundamental
- Price
- TRVI $8.07
- BBNX $25.31
- Analyst Decision
- TRVI Strong Buy
- BBNX Strong Buy
- Analyst Count
- TRVI 9
- BBNX 10
- Target Price
- TRVI $20.72
- BBNX $24.40
- AVG Volume (30 Days)
- TRVI 2.9M
- BBNX 682.8K
- Earning Date
- TRVI 11-05-2025
- BBNX 11-06-2025
- Dividend Yield
- TRVI N/A
- BBNX N/A
- EPS Growth
- TRVI N/A
- BBNX N/A
- EPS
- TRVI N/A
- BBNX N/A
- Revenue
- TRVI N/A
- BBNX $69,830,000.00
- Revenue This Year
- TRVI N/A
- BBNX $42.80
- Revenue Next Year
- TRVI N/A
- BBNX $34.58
- P/E Ratio
- TRVI N/A
- BBNX N/A
- Revenue Growth
- TRVI N/A
- BBNX 38911.17
- 52 Week Low
- TRVI $2.36
- BBNX $8.89
- 52 Week High
- TRVI $9.92
- BBNX $26.66
- Technical
- Relative Strength Index (RSI)
- TRVI 53.13
- BBNX 76.39
- Support Level
- TRVI $6.93
- BBNX $18.12
- Resistance Level
- TRVI $9.92
- BBNX $26.66
- Average True Range (ATR)
- TRVI 0.76
- BBNX 1.38
- MACD
- TRVI 0.11
- BBNX 0.64
- Stochastic Oscillator
- TRVI 37.96
- BBNX 85.37
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.